Director David Diamond resigns from Oncotelic board and audit committee

Oncotelic Therapeutics, Inc.

David Diamond resigned from the Board of Oncotelic Therapeutics on July 16, 2021, effective immediately.
He also served on the company's audit committee prior to resignation.
Resignation was not due to any disagreements with management or the Board.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Diamond

member of the Board

OTLC · Oncotelic Therapeutics, Inc.

Effective: 2021-07-16
Filed: July 20, 2021, 7:59 PM ET

On July 16, 2021, David Diamond notified the Board of Directors (the “ Board ”) of Oncotelic Therapeutics, Inc. (the “ Company ”) of his decision to resign, effective immediately, from his position as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Diamond resigned as member of the Board at Oncotelic Therapeutics, Inc..

Action: resigned
Role: member of the Board

Exact text from the filing

On July 16, 2021, David Diamond notified the Board of Directors (the “ Board ”) of Oncotelic Therapeutics, Inc. (the “ Company ”) of his decision to resign, effective immediately, from his position as a member of the Board.

View on SEC.gov

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-017253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.